Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043862 | 0.90 | KDM4E (0.48) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL10043701 | 0.90 | KDM4E (0.56) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10043738 | 0.90 | KDM4E (0.56) | NPC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10043867 | 0.89 | ABL1 (0.47) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL10043871 | 0.87 | ABL1 (0.46) | ALDH1A1KDM4EHPGDHSD17B10ABL1 | |
| SCHEMBL10043963 | 0.87 | ABL1 (0.53) | ALDH1A1KDM4EHPGDHSD17B10ABL1 | |
| SCHEMBL855108 | 0.85 | ALDH1A1 (0.41) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL10043968 | 0.84 | ABL1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10ABL1 | |
| SCHEMBL854945 | 0.83 | NPC1 (0.55) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL10043837 | 0.83 | NPC1 (0.50) | RAB9ANPC1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| EP-2252612-B1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2012-03-28 | — | — | EP | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| EP-2252612-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009105712-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | RAB9A 812/4885NPC1 2533/4885ALDH1A1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.